Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
'The Drama' plot twist, explained: What did Zendaya's character do, and what happens to her wedding? - 2The Manual for Electric Vehicles that will be hot merchants in 2023
- 3The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- 4Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 5Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
- Slims down for Maintainable Weight reduction
- Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- 1st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- Israel reports first missile fire from Yemen since start of Iran war
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- IDF strikes Tehran command centers, weapon production sites
- 6 Arranging Administrations to Change Your Open air Space
